CA2660438A1 - Genes and polypeptides relating to breast cancers - Google Patents

Genes and polypeptides relating to breast cancers Download PDF

Info

Publication number
CA2660438A1
CA2660438A1 CA002660438A CA2660438A CA2660438A1 CA 2660438 A1 CA2660438 A1 CA 2660438A1 CA 002660438 A CA002660438 A CA 002660438A CA 2660438 A CA2660438 A CA 2660438A CA 2660438 A1 CA2660438 A1 CA 2660438A1
Authority
CA
Canada
Prior art keywords
polypeptide
seq
amino acid
acid sequence
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002660438A
Other languages
English (en)
French (fr)
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Shuichi Nakatsuru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2660438A1 publication Critical patent/CA2660438A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
CA002660438A 2006-08-10 2007-08-10 Genes and polypeptides relating to breast cancers Abandoned CA2660438A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US83742806P 2006-08-10 2006-08-10
US60/837,428 2006-08-10
US84025006P 2006-08-25 2006-08-25
US60/840,250 2006-08-25
US91502207P 2007-04-30 2007-04-30
US60/915,022 2007-04-30
PCT/JP2007/065992 WO2008018642A2 (en) 2006-08-10 2007-08-10 Genes and polypeptides relating to breast cancers

Publications (1)

Publication Number Publication Date
CA2660438A1 true CA2660438A1 (en) 2008-02-14

Family

ID=38627000

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002660438A Abandoned CA2660438A1 (en) 2006-08-10 2007-08-10 Genes and polypeptides relating to breast cancers

Country Status (8)

Country Link
US (2) US8673548B2 (enExample)
EP (1) EP2057187B1 (enExample)
JP (1) JP5339291B2 (enExample)
KR (1) KR20090064378A (enExample)
BR (1) BRPI0716498A2 (enExample)
CA (1) CA2660438A1 (enExample)
SG (1) SG174071A1 (enExample)
WO (1) WO2008018642A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579246B2 (ja) 2003-09-24 2010-11-10 オンコセラピー・サイエンス株式会社 乳癌を診断する方法
BRPI0614695A2 (pt) 2005-07-29 2011-04-12 Targeted Growth Inc proteção de proteìna krp mutante negativa dominante de inibição de complexo ciclina-cdk ativo por krp do tipo silvestre
JP5514453B2 (ja) * 2008-03-04 2014-06-04 株式会社キノファーマ 発光タンパク質を用いたリン酸化酵素阻害物質のスクリーニング方法
EP2275567A1 (en) * 2009-07-15 2011-01-19 Rheinische Friedrich-Wilhelms-Universität Bonn Nucleic acid expression construct and its use as a cell proliferation marker
WO2011109262A2 (en) 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
US20120131698A1 (en) * 2010-11-12 2012-05-24 Targetd Growth, Inc. Dominant Negative Mutant Kip-Related Proteins (KRP) in Zea Mays and Methods of Their Use
WO2012142106A1 (en) 2011-04-11 2012-10-18 Targeted Growth, Inc. Identification and the use of krp mutants in plants
WO2012142116A2 (en) 2011-04-11 2012-10-18 Targeted Growth, Inc. Identification and use of krp mutants in wheat
US9725490B2 (en) 2011-07-29 2017-08-08 Tokushima University ERAP1-derived peptide and use thereof
RU2633503C2 (ru) 2011-10-28 2017-10-12 Онкотерапи Сайенс, Инк. Пептиды торк и содержащие их вакцины
EP2791335B1 (en) * 2011-12-16 2018-11-14 National University Corporation Tokyo Medical and Dental University Chimeric double-stranded nucleic acid
GB201121924D0 (en) * 2011-12-20 2012-02-01 Fahy Gurteen Labs Ltd Detection of breast cancer
WO2016011143A1 (en) * 2014-07-15 2016-01-21 Temple University Of The Commonwealth System Of Higher Education Stabilized peptide fragments from redoxin proteins as cancer biomarkers
CN104497147B (zh) * 2014-12-23 2018-07-03 四川大学 一种双受体识别的串联型穿膜肽修饰的肿瘤靶向纳米递药系统
WO2017126461A1 (ja) 2016-01-19 2017-07-27 国立大学法人徳島大学 がん治療用ペプチド及びそれを含む医薬組成物
WO2017127750A1 (en) 2016-01-22 2017-07-27 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
US11091517B2 (en) 2017-07-19 2021-08-17 Tokushima University Peptide derivative and pharmaceutical composition containing same
CN114773480A (zh) * 2022-06-07 2022-07-22 厦门大学附属翔安医院 一种抗topk第32位丝氨酸残基磷酸化的抗体
CN116082447A (zh) * 2022-09-09 2023-05-09 湖南大学 一种多肽及其制备方法
CN117757789A (zh) * 2022-09-26 2024-03-26 领星生物科技（上海）有限公司 用于抑制肿瘤生长的siRNA及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656698B1 (en) * 1999-06-30 2003-12-02 Millennium Pharmaceuticals, Inc. 12832, a novel human kinase-like molecule and uses thereof
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20050064402A1 (en) * 2000-10-03 2005-03-24 Goldsworthy Susan Mcdonald Tumor marker and methods of use
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
EP1341804A4 (en) * 2000-11-17 2005-08-24 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
WO2002059271A2 (en) * 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002357726A1 (en) 2001-11-15 2003-06-10 The Regents Of The University Of California Compositions and methods for the suppression of mammary epithelial cell proliferation
US20060241015A1 (en) * 2002-01-25 2006-10-26 Zairen Sun Cancer genes
US6833247B2 (en) * 2002-05-14 2004-12-21 Origene Technologies, Inc. Regulated prostate cancer genes
WO2003070889A2 (en) * 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
MXPA05001933A (es) * 2002-08-19 2005-04-28 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
JP2006500946A (ja) 2002-09-30 2006-01-12 オンコセラピー・サイエンス株式会社 精巣精上皮腫の診断方法
US6971476B2 (en) * 2003-09-05 2005-12-06 D B Industries, Inc. Safety harness
JP4579246B2 (ja) * 2003-09-24 2010-11-10 オンコセラピー・サイエンス株式会社 乳癌を診断する方法
EP2295601A1 (en) * 2005-02-10 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
US8053183B2 (en) * 2005-07-27 2011-11-08 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
WO2007013575A2 (en) 2005-07-28 2007-02-01 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
JP4705695B2 (ja) * 2007-10-11 2011-06-22 アストラゼネカ アクチボラグ プロテインキナーゼｂ阻害剤としてのピロロ［２，３−ｄ］ピリミジン誘導体
MX2011004414A (es) * 2008-10-30 2011-06-21 Oncotherapy Science Inc Derivados de 7-hidroxi-benzoimidazol-4-il-metanona e inhibidores de cinasa que enlaza pdz que contienen los mismos.

Also Published As

Publication number Publication date
WO2008018642A3 (en) 2008-04-03
EP2444417A1 (en) 2012-04-25
SG174071A1 (en) 2011-09-29
BRPI0716498A2 (pt) 2015-01-27
US20140228238A1 (en) 2014-08-14
EP2057187B1 (en) 2016-12-28
US8673548B2 (en) 2014-03-18
US20110135647A1 (en) 2011-06-09
JP2010500003A (ja) 2010-01-07
EP2057187A2 (en) 2009-05-13
JP5339291B2 (ja) 2013-11-13
WO2008018642A2 (en) 2008-02-14
KR20090064378A (ko) 2009-06-18
US9187557B2 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
US9187557B2 (en) Genes and polypeptides relating to breast cancers
JP4921522B2 (ja) 非小細胞肺癌の診断のための方法
US20110152345A1 (en) Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
US20110263012A1 (en) Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
JP2010501172A (ja) 肺癌に対する予後マーカーおよび治療標的
JP2010512730A (ja) 肺癌の腫瘍マーカーおよび治療標的としてのｔｔｋ
US20100184047A1 (en) Screening and therapeutic method for nsclc targeting the cdca8-aurkb complex
WO2008023841A1 (en) Breast cancer-associated gene, melk, and its interactions with bcl-g
CN101068935B (zh) 与乳腺癌相关的基因和多肽
CN101528768A (zh) 与乳腺癌相关的基因和多肽
EP2444417B1 (en) Genes and polypeptides relating to breast cancers
US20120010266A1 (en) Tbc1d7 as tumor marker and therapeutic target for cancer
US20120214174A1 (en) Gene and polypeptide relating to breast cancer
WO2008020653A1 (en) Use of holliday junction-recognizing protein related to cancer
WO2010047028A1 (en) Screening method of anti-lung or esophageal cancer compounds

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130812